Nanosphere (NSPH) reported quarterly earnings results on Monday, May-16-2016. The company reported $-0.55 earnings per share for the quarter, missing the analyst consensus estimate by $-0.06. Analysts had a consensus of $-0.49. The company posted revenue of $6.60 million in the period, compared to analysts expectations of $6.50 million. The company’s revenue was up 43.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-1.29 EPS.
Many Wall Street Analysts have commented on Nanosphere. Rodman & Renshaw Initiated Nanosphere on Mar 8, 2016 to “Buy”, Price Target of the shares are set at $2.Shares were Reiterated by Chardan Capital Markets on Feb 25, 2016 to “Buy” and Lowered the Price Target to $ 1.65 from a previous price target of $3.30 .
Nanosphere opened for trading at $0.78 and hit $0.78 on the upside on Friday, eventually ending the session at $0.78, with a gain of 1.30% or 0.01 points. The heightened volatility saw the trading volume jump to 19,462 shares. Company has a market cap of $9.6 M.
Nanosphere Inc. is engaged in developing manufacturing and marketing an advanced molecular diagnostics platform the Verigene System which enables genomic and protein testing on a single platform. The Company’s nanoparticle technology provides the solution to run multiple tests simultaneously on the same sample. The Verigene System includes a bench-top molecular diagnostics workstation that is a universal platform for genomic and protein testing. The Verigene System provides for multiple tests to be performed on a single platform including both genomic and protein assays from a single sample. The Verigene System is comprised of a microfluidics processor a touchscreen reader certain disposable consumables used in sample preparation target amplification and test cartridges. The Company is focused on the infectious disease diagnostics market.